Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis
BackgroundThis study conducted a network meta-analysis to evaluate and rank the safety and efficacy of programmed cell death protein-1 (PD-1) inhibitors for patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).MethodsA systematic search was conducted in PubMed, Embase, and Co...
Saved in:
| Main Authors: | Yunnan Zhang, Wenxing Peng, Wei Yang, Wenzhou Zhang, Yannan Fan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1500954/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effective analysis of sugemalimab plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥5
by: Yalan Zhang, et al.
Published: (2025-08-01) -
A conceptual model for advanced/metastatic gastric or gastroesophageal junction cancer: a review of qualitative studies and results from patient interviews
by: France Ginchereau Sowell, et al.
Published: (2025-01-01) -
Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
by: Zhifeng Zhou, et al.
Published: (2025-05-01) -
First-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: a meta-analysis of phase 3 trials
by: Yuxuan Lin, et al.
Published: (2025-05-01) -
Efficacy and safety of pembrolizumab in advanced gastric and gastroesophageal junction cancer: a systematic review and meta-analysis
by: Xiaoying Ji, et al.
Published: (2025-03-01)